• Jun Guo, Xianhuan Zhang, Yanan Zhu, and Qiong Cheng.
• Department of Emergency, Taizhou Hospital of Zhejiang Province, Zhejiang Province, China.
• Medicine (Baltimore). 2022 Mar 18; 101 (11).

BackgroundLevosimendan and dobutamine are extensively used to treat sepsis-induced cardiomyopathy. Previous studies on whether levosimendan is superior to dobutamine are still controversial. We performed a protocol for systematic review and metaanalysis to compare the efficacy and safety of levosimendan versus dobutamine for the treatment of sepsis-induced cardiomyopathy.MethodsThis protocol follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses protocol statement. We will search the following databases: PubMed, Embase, Web of Science, Cochrane Library, China National Knowledge Infrastructure, Wanfang Database, Weipu Journal Database, and Chinese Biomedical Literature Database. The search time will be set from database establishment to February 2022. After literature screening, 2 reviewers will extract data from the respects of general information, methodology, and results. Risk of bias is assessed using the Cochrane Risk of Bias Tool for randomized controlled trials. We will apply RevMan 5.4 software for statistical analysis.ResultsThe results will be submitted to a peer-reviewed journal once completed.ConclusionSeptic patients with myocardial dysfunction may partly benefit from levosimendan than dobutamine, mainly embodied in cardiac function improvement.Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

20 keywords...

hide…